Indian experience with immunotherapy in sarcoma and gastrointestinal stromal tumors: a retrospective study-Reference-Cited by-同舟云学术

Indian experience with immunotherapy in sarcoma and gastrointestinal stromal tumors: a retrospective study

Published:2022-06 Issue:5 Volume:8 Page:
ISSN:2056-5623
Container-title:Future Science OA
language:en
Short-container-title:Future Science OA

Author:

Reddy Rohit¹^ORCID,Velagapudi Raja Mounika²,Chitikela Sindhura Durga¹,Barwad Adarsh³,Shrivastava Shakti¹,Dhamija Ekta⁴,Shamim Shamim Ahmed⁵,Tripathy Sarthak⁵,Pandey Rambha⁶,Rastogi Sameer⁷^ORCID

Affiliation:

1. Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India

2. Department of Internal Medicine, Venkateshwara Institute of Medical Sciences, Uttar Pradesh, 244236, India

3. Department of Pathology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India

4. Department of Radio diagnosis, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India

5. Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India

6. Department of Radiation Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India

7. Sarcoma Medical Oncology Clinic, Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India

Abstract

Aim: To study the role of check point inhibitors (CPI) in sarcoma and gastrointestinal stromal tumors. Materials & methods: Retrospective data of 15 patients diagnosed with advanced sarcoma or gastrointestinal stromal tumors and treated with CPI. Results: 3/14 patients (21.4%) responded to treatment with a disease control rate of 42.8% (6/14). After a median follow-up of 14 months (range: 2–24 months), 11 (73.3%) patients progressed, the median progression-free survival was 4 months (95% CI: 1.7–6.3) and median overall survival was 14 months (95% CI: 2.6–25.7). Only one patient experienced a grade IV adverse event. Conclusion: Our data represent the first real-world application of CPI in sarcoma from India. We believe that CPI should be further evaluated in clinical trials.

Publisher

Future Science Ltd

Subject

Biotechnology

Link

https://www.future-science.com/doi/pdf/10.2144/fsoa-2021-0117

Reference29 articles.

1. Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium

2. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

3. CTLA-4 and PD-1 Pathways

4. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

5. A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers;Molecular Cancer;2023-04-18

2. Antineoplastics;Reactions Weekly;2022-09-24